1 BDF 9148 is a newly synthesized congener of DPI 201-106 in which the piperazidinyl moiety has been replaced by an azetidine-3-oxy-moiety. The inotropic effect of both drugs was studied as well as their influence on the action potential, by use of standard microelectrode techniques.
Introduction
Cardiac glycosides are effective in congestive heart failure, but their safety margin is small and toxic side-effects are not uncommon. Inhibitors of phosphodiesterase III have been tried as an alternative therapeutic principle for this disease. However, these drugs are potentially arrhythmogenic because they increase the adenosine 3': 5'-cyclic monophosphate (cyclic AMP) level of the myocardial cells. Furthermore, in the failing heart the number of fi-adrenoceptors is reduced (Bristow et al., 1982) and the stimulation of adenylate cyclase is impaired by an increased concentration of G,-proteins (Feldman et al., 1987) . Therefore, the effectiveness of phosphodiesterase inhibitors is reduced in end-stage heart failure (Feldman et al., 1987; Bohm et al., 1988) , and there is still a need for new positive inotropic drugs which are clinically effective and safe in congestive heart failure.
An increased intracellular sodium concentration inhibits the diastolic calcium extrusion via the sodium-calcium exchange mechanism. Therefore, drugs which increase the sodium influx may increase the contractile force. The positive inotropic effect of naturally occurring sodium channel activators cannot be exploited therapeutically, because these drugs cause a dramatic prolongation of the action potential duration, can trigger afterdepolarizations and thus induce arrhythmias (Honerjdger, 1982) . However, the piperazinyl-indole DPI 201-106 has been used successfully in some recent clinical trials (Kostis et al., 1987; Butrous et al., 1988; Hogan et al., 1988) . BDF 9148, systematic name 4-[3-(1-diphenylmethylazetidine-3 -oxy)-2 -hydroxy -propoxy] -1 -H -indole-2 -carbonitrile, is a recently synthesized derivative, where the piperazinyl moiety of DPI 201-106 has been replaced by an azetidine-3-oxy-moiety ( Figure 1 ). Several preliminary communications (Armah et al., 1990a,b; Brasch, 1990; Brasch & Iven, 1990) ,'-. Macmillan Press Ltd, 1991 I Author for correspondence. present paper we compare the effects of BDF 9148 and DPI 201-106 in guinea-pig isolated atria and papillary muscles.
Methods

Experimental procedure
Male guinea pigs (300-500 g) were killed by a blow on the head. The hearts were rapidly removed and right or left atria or papillary muscles from the right ventricle were dissected in cold, oxygenated Krebs-Henseleit solution. The muscles were then mounted in 20 ml organ baths filled with Krebs-Henseleit solution of the following composition (mmol '): NaCl 117.6, KCL 5.8, CaCI2 1.8, MgSO4 1.2, NaH2PO4 1.2, NaHCO3 25 and dextrose 5.5. They were kept at 32 + 0.20C and constantly gassed with 95% 02 and 5% CO2. The low temperature was chosen because at 370C the oxygen demand is greater and many preparations show a marked decline of the contractile force during a control period of some hours. This decline is negligible at 320C which, therefore, is a commonly used temperature for in vitro experiments with heart muscle. The resting tension was adjusted to IOmN.
Right atria were allowed to beat spontaneously. Left atria and papillary muscles were stimulated at a rate of 1 Hz via platinum electrodes with square pulses of 1 ms duration and 1.5 times threshold voltage. The force of contraction was registered isometrically by a K30 force-displacement transducer (Hugo-Sachs, Hugstetten, F.R.G.) and the isometric contraction curve was displayed on a Hellige Helcoscriptor (Hellige, Freiburg, F.R.G.). The time to peak force (t1) and the relaxation time (t2) were measured at 10% of the maximum of the isometric contraction curve. Action potentials (AP) from papillary muscles were recorded with standard glass microelectrodes which were filled with 3 M KCI and had a tip resistance of 5-10 MCI. The maximum depolarization velocity 
Results
Chronotropic effect
At the beginning of the experiments, the beating frequency of right atria ranged between 160 and 170 beats per minute (b.p.m.). Increasing the concentration of BDF 9148 stepwise in 20min intervals up to 3 x 10-6moll-' caused no-significant change of the contraction rate. Only with the final concentration of 10 5 mol I1 a slight reduction to 144 + 5 b.p.m. was observed ( Figure 2 ). DPI 201-106, in concentrations between 1O-7mol1-' and 10-5mol1-l, caused a concentrationdependent decrease of the beating frequency from 161 + 5b.p.m. to 86 + 7b.p.m. (Figure 2 ). The solvent DMSO, which was added cumulatively in 6 control experiments up to a final concentration of 0.75%, did not change the contraction rate significantly (data not shown).
Inotropic effect Cumulative concentration-response curves (dosing interval 40min) for the positive inotropic effect of BDF 9148 and DPI 201-106 are shown in Figure 3 . In left atria, BDF 9148 increased the force of contraction from 4.3 + 1.0mN to 11.5 + 1.8 mN and DPI 201-106 caused an increase from 2.5 + 0.5 mN to 10.9 + 0.7 mN. We cannot explain why the predrug contractile force was so much smaller in the DPI 201-106-treated muscles, but we are confident that a technical mistake in the experiments can be excluded. Due to this discrepancy, the % force increase obtained with BDF 9148 (+ 167%) was smaller than the % increase produced by DPI 201-106 (+ 336%) though the maximum developed force was nearly identical with both drugs. Also, the EC50 values of the two compounds were not significantly different. For BDF 9148 an EC50 of 1.32 x 10-7moll-' was calculated (95% confidence interval 0.46-3.78 x 10 7moll-1) and the corresponding value for DPI 201-106 was 2.6 x 10-7mol P1 (2.0-3.4 x 10-7mollP1).
In papillary muscles, BDF 9148 increased the contractile force from 2.0 + 0.6mN to 4.4 + 0.8 mN (+ 120%), and DPI 201-106 produced an increase from 2.6 + 0.4mN to 5.8 + 0.8 mN (+123%). The EC50 for BDF 9148, however, (7 x 10-7moll-P; 95% confidence interval 5.6-8.8 x 10-7moll-') was significantly greater than for DPI 201-106 (2.8 x 10-7moll-P; 95% confidence interval 2.2-3.5 x 10-7moll-).
Both drugs also changed the shape of the isometric contraction curve. Typical examples are shown in Figure 4 . The main effect was a concentration-dependent prolongation of the relaxation time of atria and papillary muscles (Table 1) . In both cases, the maximum increase caused by DPI 201-106 was greater than the maximum effect of BDF 9148. The time to peak force of atria was also prolonged by both drugs while the time to peak force of papillary muscles was not affected by BDF 9148 and slightly shortened by DPI 201-106.
Interaction of BDF 9148 with other drugs
After addition of 10-6 mol P-BDF 9148 to the organ bath, the force of contraction of left atria increased from 4.3 + 0.9 mN to 10.0 + 1.2 mN within 20 min and remained nearly constant thereafter ( Figure 5) . A similar time course was observed for the prolongation of the relaxation time from 85 + 6 ms to 140 + 7 ms. After 1 h of drug exposure, the effects of BDF 9148 could not be reversed or reduced by a 30min washout period ( Figure 5) .
In 6 atria, the effect of 10-6mol1-l BDF 9148 was tested in the presence of 4 x 10-6mol-1 propranolol. The fl-blocker was added 30min before BDF 9148 and did not attenuate the positive inotropic effect of the latter. In these experiments the contractile force increased from 2.4 + 0.3 mN to 6.9 + 1.0 mN.
The relaxation time, however, was prolonged much less (from However, when both drugs were removed from the organ bath by washout, the force of contraction and the relaxation time started to increase again and reached final values that were similar to the maximum effects observed in the presence of BDF 9148 (Figure 6) .
A small concentration of BDF 9148, 3 x 10-8mollP', which by itself caused only a 32% increase of the contractile force, shifted the concentration-response curve for the positive inotropic effect of ouabain in atria to the left (Figure 7) . In unpretreated muscles, ouabain increased the force of contraction from 2.7 + 0.2mN to 12.4 + 1.3mN and the ECQO was 3.21 x 10 7mollF' (95% confidence interval 2.86-3.61 x 10-7moll-'). After preincubation with BDF 9148 for 1 h, the maximum effect of ouabain was not affected, i.e. the force increased from 4.71 + 0.9 mN to 12.9 + 1.7 mN, but the Table 2 Concentration of BDF 9148 (umolkg-')in left atria after incubation with the drug for 2-30min and subsequent washout Table 3 ). In the single concentration experiments, the total duration of the BDF 9148 exposure was shorter than in the cumulative concentration-response experiments (30 min versus at least 80min), but admittedly this is not a really satisfying explanation for the variability of the drug effect. When Table 3 (Control) and their mean changes (A) 10, 20, 30 or 60 min after addition of each drug concentration are shown (x ± s.e.mean; n = 6). Asterisks indicate changes that are statistically significant (P < 0.05; t test for paired data). Abbreviations: MRP = membrane resting potential; APA = action potential amplitude; Vmax = maximum depolarization velocity; APD20, APD80 = action potential duration at 20% and 80% of full repolarization; FRP = functional refractory period. 10-5moll-1 (5) BDF 9148 after 20min exposure to each drug concentration. Although there was a small increase of the action potential amplitude with 10 5moll-in this experiment, the mean effect of BDF 9148 on this parameter was not statistically significant (see Table 3 ). (b) Control AP (1) and effect of 3 x 10-6moll-1 (2) and 10-mol 1 '(3) DPI 201-106 after 60min exposure to each drug concentration. The corresponding JP..values are given in the insets.
3 x 10-6mol-1 tetrodotoxin was added 30 min after 10-5 mol 1-1 BDF 9148, the influence of the latter was promptly reversed (Table 3) (Honerjiger, 1982) . As the effect of BDF 9148 was promptly reversed by the sodium channel inactivator tetrodotoxin, an increased sodium influx seems to be the most likely explanation for the druginduced increase of contractility. Recent measurements of the sodium current in rat isolated myocytes have confirmed this mechanism of action (Honerjiiger et al., 1990) . The leftward shift of the concentration-response curve of ouabain produced by BDF 9148 fits into the picture because an inhibition of the Na'-K+-ATPase should have a greater effect when the sodium load of the cells is increased. Similar interactions with cardiac glycosides have been observed with DPI 201-106 (Scholtysik et al., 1989 ) and veratridine (Honerjager & Reiter 1975) .
BDF 9148 and DPI 201-106 prolonged the action potential duration at all stages of repolarization. , this is a well known effect (Buggisch et al., 1985; Scholtysik et al., 1985; Kohlhardt et al., 1987; Kihara et al., 1989) which is best explained by a slowed inactivation of the inward sodium current. The increase in action potential duration probably accounts for the associated prolongation of the functional refractory period. In comparison to some ceveratrum alkaloids, which cause an excessive prolongation of the terminal repolarizaton phase (Honerjdger, 1982) , the overall effect of BDF 9148 and DPI 201-106 on the action potential duration is small. Wang et al. (1990) have shown that the enantiomers of DPI 201-106 have opposite effects on the sodium channel. (S)-DPI increases the peak inward current and slows its inactivation while (R)-DPI reduces the peak current. Thus the maximum effect of racemic DPI, which was used in our experiments, is limited by a kind of auto-inhibitory mechanism, which may explain the low arrhythmogenicity of this drug. A similar mechanism could limit the action potential prolongation by racemic BDF 9148 (Buggisch et al., 1985) , which is also very lipophilic.
There was one major difference between BDF 9148 and DPI 201-106: while the former had only a small effect on the beating frequency of right atria, a concentration-dependent negative chronotropic effect was seen with DPI 201-106. This drug binds to vascular (Hof & Hof, 1985) and cardiac (Holck & Osterrieder, 1988; Siegl et al., 1988) calcium channels and reduces the slow inward current in slow response action potentials (Buggisch et al., 1985) . Thus, calcium antagonism is a probable explanation for the negative chronotropic effect of DPI 201-106. It may also be the cause of the slight reduction of the atrial rate that was observed with the higher concentration of BDF 9148 in our experiments. The finding that beyond 10-7mollP, BDF 9148 reduces the calcium current in myocytes (Pfeifer & Ravens, 1990) points in this direction. If this explanation is accepted, a comparison of the negative chronotropic effects of and BDF 9148 suggests that the calcium antagonistic properties of the latter are much weaker than those of the parent compound. However, before a detailed comparison of the influence of both drugs on the cardiac calcium channels has been made, such an assumption remains speculative.
We observed only an increase of the action potential duration in the presence of BDF 9148, while Armah et al. (1990a,b) have described a biphasic effect, i.e. a transient prolongation followed by a gradual shortening. The discrepancy may be due, at least in part, to methodological differences. While we increased the concentration of BDF 9148 at 20min intervals, Armah et al. (1990ab) observed the effect of a single concentration for 90min. In their experiments action potential shortening usually began after 30-60min of drug exposure. Thus, even the 1 h observation period with 10-5mol -1 BDF 9148 in our experiments may have been too short for the development of a biphasic drug effect. However, if the increase of the action potential duration is indeed transient in vivo, this could explain why no increase of the Q-T interval of the ECG is seen in the presence of BDF 9148 (Muster & Raap 1990) while DPI 201-106 usually causes a prolongation (Ruegg & Nuesch, 1987; Kostis et al., 1987) .
To sum up, BDF 9148 is an ionotropic compound structurally related to DPI 201-106. Our results confirm and extend earlier findings which support the hypothesis that both drugs increase the contractile force via a prolongation of the open state of the sodium channel. BDF 9148 differs from its parent compound mainly by a much weaker influence on the spontaneous beating frequency. The drug may be beneficial in the treatment of congestive heart failure and its in vitro and in vivo effects certainly deserve further investigation.
